BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:The Economics of Genomics - Dr Ed Wilson and Dr Brett Doble\, Camb
 ridge Centre for Health Services Research
DTSTART:20160202T123000Z
DTEND:20160202T133000Z
UID:TALK66069@talks.cam.ac.uk
CONTACT:Dr James Hadfield
DESCRIPTION:Next up are Ed Wilson\, Brett Doble from the . They are talkin
 g about how economic evaluation and assessment of New genomic tests and so
 -called individualised medicines have the capacity to improve patient outc
 omes\, but incur added costs to the NHS.  This is important because choosi
 ng to allocate the NHS’s funds to treating one group of patients means t
 hey cannot be used to treat another: the more we spend on cancer therapies
  the less there is to spend on patients with other diseases.  Economic eva
 luation attempts to estimate the added costs associated with a new treatme
 nt\, and compare this with the added improvement in outcomes to determine 
 whether the new treatment represents good value for money for taxpayers.\n
 In this seminar Ed & Brett will give a brief overview of the methods of ec
 onomic evaluation\, explaining their importance in ensuring the maximum be
 nefit for the funds available.  They will then show how these tools should
  be applied in the economic assessment of genomic medicine in oncology. Sp
 ecific challenges are discussed and an example evaluating multiplex target
 ed sequencing for selecting targeted treatment in lung adenocarcinoma is p
 resented.\n \nSpeaker Bios:\nEd is a Senior Research Associate in Health E
 conomics at the Cambridge Centre for Health Services Research\, University
  of Cambridge. He trained in economics and then health economics at the Un
 iversity of York and holds a PhD in Health Economics from the University o
 f East Anglia.  He has expertise in decision analytic modelling\, economic
  evaluation alongside clinical trials\, option appraisal and programme bud
 geting and marginal analysis (PBMA).  Ed has applied these in a variety of
  disease areas including obesity\, stroke\, dementia\, lupus\, IVF\, erect
 ile dysfunction\, essential thrombocythaemia\, diabetes\, actinic keratosi
 s\, malignant melanoma\, prostate cancer\, cholecystitis\, idiopathic pulm
 onary fibrosis and ulcerative colitis. His methodological research is in t
 he area of efficient research design\, specifically value of information a
 nalysis\, a quantitative approach to setting research priorities making us
 e of uncertainty in the results of economic evaluations to quantify the ex
 pected return on investment in further research.\n\nBrett is a health econ
 omist\, with international experience in academic research\, consulting an
 d the pharmaceutical industry. He received his BSc in Biochemistry and MSc
  in Clinical Epidemiology and Biostatistics from McMaster University in Ca
 nada where he was a Canadian Institutes of Health Research Strategic Train
 ing Fellow for Drug Safety and Effectiveness. He is currently completing h
 is PhD at the Centre for Health Economics\, Monash University in Australia
  where he was the recipient of the Donald Cochrane Research Scholarship. R
 ecently\, Brett also worked with the Garvan Institute of Medical Research 
 in Australia on consulting projects assessing the economic impacts of popu
 lation-wide whole genome sequencing. He has an expertise in the economics 
 of genomic medicine and a particular interest in its applications in oncol
 ogy and monogenic diseases. He has completed a number of economic evaluati
 ons of health technologies using decision analytic modelling and has an in
 terest in further undertaking trial-based economic evaluations and develop
 ing economic methods for the assessment of diagnostic tests within the gen
 omics context. Brett also has an interest in health outcomes research\, sp
 ecifically the use of ‘mapping’ to generate health state utility value
 s.
LOCATION:CRUK Cambridge Institute room 009\, Li Ka Shing Centre\, Robinson
  Way\, Cambridge CB2 0RE
END:VEVENT
END:VCALENDAR